Vicuron dalbavancin 90-day extension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vicuron continues to plan a first-quarter 2006 launch of its lipoglycopeptide antibiotic dalbavancin despite FDA's 90-day extension of its original priority review user fee date of June 21. FDA reset the action date after deeming the company's responses to chemistry, manufacturing and controls questions to be a major amendment. The firm is seeking an indication for treatment of chronic skin and soft tissue infections. Vicuron has another antibiotic NME pending at FDA: anidulafungin has been "approvable" since May 2004 for esophageal candidiasis; the firm plans to respond in the second quarter...
You may also be interested in...
Pfizer dalbavancin "approvable"
Pfizer's lipoglycopeptide antibiotic dalbavancin is "approvable" Sept. 21 for treatment of chronic skin and soft tissue infections. The agent is receiving a priority review but FDA extended its action date by 90 days in May following a major amendment relating to chemistry, manufacturing & controls (1Pharmaceutical Approvals Monthly May 2005, In Brief). Pfizer's acquisition of innovator Vicuron closed Sept. 11...
Licensing In Brief
Pfizer expands anti-infective portfolio with Vicuron buy: Pfizer's $1.9 bil. acquisition of Vicuron includes the near-term antibiotic candidate dalbavancin, currently pending at FDA with a Sept. 21 user fee date . Vicuron has targeted an early 2006 launch for the once-weekly therapy for chronic skin and soft tissue infections (1Pharmaceutical Approvals Monthly May 2005, In Brief). Announced June 16, the merger builds on Pfizer's experience in the anti-infective market and extends its existing portfolio, which includes the antifungal agents Diflucan (fluconazole) and Vfend (voriconazole), and the antibiotics Zithromax (azithromycin) and Zyvox (linezolid). The Vicuron deal also gives Pfizer a new antifungal agent, anidulafungin, deemed "approvable" at FDA in May 2004. The firms' combination marks the culmination of a six-year collaboration to develop new antibiotic candidates…
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.